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Acute ischemic stroke in a pediatric patient is a complex disease with a variety of etiologies that differ 
from adults. Though rare, they are a real phenomenon with potentially devastating consequences. 
Some treating institutions are using anti-thrombotic drug therapy with unclear benefits. Available 
literature, which is limited to case reports and retrospective reviews of databases, clouds this topic 
with both positive and negative outcomes. Emergency department management should focus on 
stabilization and resuscitation with immediate involvement of a pediatric neurologist and intensivist. 
The decision to use anti-thrombotic drug therapy, including anti-platelet drugs and thrombolytics, 
should be in consult with the specialists involved until randomized controlled trials determine their 
safety and efficacy in the pediatric population.
[WestJEM. 2008;9:225-227.]
INTRODUCTION
Acute ischemic stroke (AIS) in a pediatric patient is a 
rare medical emergency with an incidence of only 2-3 per 
100,000.1 Cognitive and behavioral sequelae frequently arise 
with social implications and effects on daily living.2 The 
etiologies of stroke in a child are more varied than in adults 
and are not always due to acute clot formation or hemorrhage. 
Literature on this topic, including the use of anti-thrombotic 
therapy for children presenting with AIS, is sparse. Studies in 
the adult population show anti-thrombotic drugs, including 
aspirin, are effective when administered using recommended 
guidelines.3 The role of thrombolytics is controversial with 
conflicting evidence.4,5,6 This case report describes an 11-year-
old boy who presented to the emergency department (ED) of a 
small rural community with the diagnosis of an acute ischemic 
stroke. After transfer to a children’s hospital and an exhaustive 
workup, the etiology of his stroke remained unclear. At four-
month outpatient follow-up, the patient had only minimal 
left arm weakness. Background information on AIS in the 
pediatric population is presented, including ED management 
and the role of anti-thrombotic drug therapy.
CASE
An 11-year-old Hispanic male presented to the ED 30 
minutes after the sudden onset of headache, left-sided weakness 
and dysarthria. His vital signs were within normal limits. Left 
arm and leg strength were 2/5 with a noticeable facial droop. 
Cardiac exam showed a regular rate and rhythm with no 
murmurs. Chest was clear and abdomen was soft. No petechiae 
were noted on his skin. Fingerstick blood glucose was normal. 
A CT scan of the head showed edema to the right frontal 
lobe without evidence of hemorrhage. Transfer for higher 
level of care was initiated with the presumptive diagnosis of 
acute ischemic stroke. A long transport time placed him at the 
nearest children’s hospital eight hours after symptom onset. An 
emergent MRI showed findings consistent with a right frontal 
lobe and basal ganglia ischemic infarction (Figure 1). The 
patient was given aspirin, empiric intravenous antibiotics and 
antiviral medications in the ED. A thorough work-up ensued 
in the pediatric intensive care unit. An MRA of the brain, 
carotid Doppler and echocardiogram were normal. The lumbar 
puncture, ECG, CBC, chemistry panel, liver enzymes, cardiac 
enzymes and urine drug screen were normal, as were the SLE 
panel, Protein C and S, Factor V Leiden, anti-phospholipid 
antibodies, anti-thrombin III and coagulation profile, metabolic 
screening tests, blood and CSF cultures. The patient remained 
stable for the first two days and regained some motor strength. 
His hospital stay was complicated by a worsening headache. 
The CT demonstrated increased intracranial pressure that 
resolved following treatment with mannitol and steroids. After 
four weeks of extensive testing and rehabilitation, the etiology 
for his ischemic stroke remained elusive. The patient expended 
significant time and effort with a physical therapist. Upon 
discharge, he had regained the ability to walk and was able to Volume IX, n o . 4  :  November 2008                                            226                                      Western Journal of Emergency Medicine
move his left arm above his head. At his four-month follow-up, 
he had mild residual left arm weakness with no deficits in his 
gait or speech.
DISCUSSION
AIS in a pediatric patient is defined as a stroke occurring 
between the ages of one month and 18 years. This relatively 
rare condition varies geographically with occurrence in the 
United States at 2-3 per 100,000 patients.1 By contrast, the 
overall incidence rate for total stroke (first-ever and recurrent 
of all ages) was 269 per 100,000 population.7 Eighty percent 
of adult strokes are due to ischemia. While ischemic strokes 
in adults are usually thrombotic or embolic in nature, they 
may also be caused by hypoperfusion states. Cryptogenic 
strokes comprise 30 to 40% of all adult ischemic strokes and 
approximately 50% in children.2,8 
Acute ischemic strokes in children most commonly 
occur between the ages of 1-5 years and least commonly in 
the extremes (< 1 year and > 15 years).9 Focal neurological 
signs occur in three-quarters of patients, with hemiplegia the 
most common.9 Despite the fact that infection accounts for 
26% of cases, fever is present only 11% of the time.9 The risk 
factors for stroke in children are congenital heart disease, 
infection, prothrombotic disorders, trauma, acquired and 
congenital vascular disease, sickle cell disease, metabolic 
disorders and mitochondrial disease.9 Vascular disease alone 
accounts for one-third of cases, while metabolic disorders 
and prothrombotic disorders comprise 18% and 13% of cases 
respectively.9 Trauma makes up an additional 11% of cases.9 
At least one risk factor is present in 90% of patients with 
almost 25% of patients having more than one.9
There appears to be demographic variation with a 
predilection for both gender and ethnicity. A seasonal variation 
may exist, as the disease most commonly occurs during the 
summer and least commonly during the winter.9 African-
Americans have a significantly higher risk of suffering from 
both ischemic stroke and hemorrhagic strokes.10 Males carry 
a significantly higher risk of suffering all stroke subtypes 
compared to females.10
ED management of a child suffering from an ischemic 
stroke should focus on stabilization and transfer to an 
appropriate facility for specialty care. Stabilization begins 
with securing the airway, providing supplemental oxygen, 
establishing IV access and monitoring vitals signs and mental 
status. An emergent CT of the head in the ED should not 
be delayed. An ECG, CXR and lab work should be sent, 
including a complete blood count, blood and CSF cultures, 
chemistry, liver enzymes, cardiac markers, coagulation 
factors, urine analysis and urine drug screen. Empiric 
intravenous antibiotics and antivirals, maintenance fluid with 
an isotonic, non-dextrose containing fluid must be initiated in 
the ED. 
Anti-platelet drugs are widely used in adults after 
literature has shown they reduce the rate of strokes.2 Although 
randomized controlled trials with children have not been 
conducted, anti-platelet drugs are used in some centers to 
reduce the recurrence rate of stroke.2 Adverse effects, such as 
severe bleeding or the precipitation of Reye’s syndrome, are 
rare.2 The use of anti-thrombotic drugs remains controversial 
in the pediatric literature and is not the standard of care.3 
However, anti-thrombotic drugs are being given to pediatric 
patients at some institutions despite a paucity of supporting 
literature. The benefits are unclear, and it seems their use is 
based on adult studies, case reports and expert opinion.11 One 
study showed 1.6% of pediatric AIS patients admitted between 
2000 and 2003 received thrombolytic therapy.1 The children 
receiving thrombolytics had significantly higher medical 
costs, were less likely to be discharged home and had higher 
overall mortality rates.1 Shortcomings of these findings were 
noted, including the small sample size and unknown severity 
of any of the patients at the time of presentation. Conversely, 
several case reports have been published showing potential 
benefits using thrombolytic therapy in children, including 
success stories across a wide age range and administration of 
thrombolytics well outside of the standard three-hour window 
used in adults.11,12 
There are numerous etiologies for acute ischemic 
stroke in the pediatric population. Arterial dissection is one 
important cause. While most dissections occur in the internal 
carotid artery, children may dissect intracranially. MRI 
and contrast MRA show the anatomy without the risks of 
traditional angiography or radiation. Duplex ultrasonagraphy 
is useful, but CT angiogram still remains the gold standard 
for further investigation for suspected arterial dissection.13 
Secondly, cerebral venous sinus thrombosis may cause 
strokes in children. This commonly develops from extension 
Figure.  Diffusion Weighted MRI consistent with a right frontal 
lobe and basal ganglia ischemic infarction
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of infections, including acute otitis media, mastoiditis, 
pharyngitis, sinusitis, or meningitis. If infection is suspected, 
appropriate intravenous antimicrobials to include a third-
generation cephalosporin, vancomycin and acyclovir should 
be initiated. Additionally, infectious vasculitis may occur 
from chronic infections such as tuberculous meningitis or 
rickettsial infection. Vasculitis may also be seen with common 
viral illnesses such as varicella and coxsackie. Lastly, cerebral 
vasculitis should be considered in children with either 
ischemic or hemorrhagic stroke, as well as strokes associated 
with fever or rash.13 While erythrocyte sedimentation rate may 
be used as a screening tool, its interpretation should be used 
with caution since it does not exclude all vascular etiologies 
for ischemic stroke. There is no literature to support the 
empiric use of steroids; however, they may be given to treat 
cerebral edema or a vasculitic cause of stroke.
The rate of recurrence for childhood stroke may be as high as 
30% and is dependent upon the etiology of the stroke.2 Children 
with a hypercoagulable disorder or a vascular diagnosis have a 
higher likelihood of recurrent stroke. Sickle cell disease patients 
have a 40% chance of repeat stroke, while children with arterial 
dissection have a recurrence rate of 12%.13
Children who suffer AIS generally recover better than 
adults, but the effects may still be long lasting and detrimental.14 
While children who suffer a stroke have good educational and 
mobility outcomes, they have poorer outcomes when it comes 
to communication, socialization and activities of daily living.14 
Social and economic consequences, including decreased ability 
to work and lifelong disability, may arise. This is even more 
profound in children having a recurrence. The financial impact 
of these consequences has yet to be analyzed.
CONCLUSION
AIS in the pediatric patient is a rare but potentially 
devastating disease. The lack of research in this area is 
apparent. There is only anecdotal evidence for the use of anti-
thrombotic drugs in the management of children with ischemic 
strokes, unlike the evidence for treating adult ischemic 
strokes. Due to the high rate of recurrence anti-platelet drugs 
should be considered and initiated in the ED.
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